Patents Assigned to BOUNDLESS BIO, INC.
  • Checkpoint kinase 1 (CHK1) inhibitors and uses thereof
    Patent number: 12527790
    Abstract: Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a Chk1 inhibitor disclosed herein.
    Type: Grant
    Filed: June 1, 2023
    Date of Patent: January 20, 2026
    Assignee: BOUNDLESS BIO, INC.
    Inventors: Anthony B. Pinkerton, Stephen Todd Meyer, Jacques Mauger, Yen Pham Hong Truong, Rachelle Janette Elsdon
  • Replication stress pathway agent compositions and methods for treating cancer
    Patent number: 12246017
    Abstract: Provided herein are methods of treating cancer in a subject, wherein the cancer is extrachromosomal DNA-positive (ecDNA-positive) or therapeutically resistant, the method comprising administering to the subject a therapeutically effective amount of a replication stress (RS) pathway agent alone or in combination with a targeted therapeutic.
    Type: Grant
    Filed: March 24, 2023
    Date of Patent: March 11, 2025
    Assignee: BOUNDLESS BIO, INC.
    Inventors: Christian Hassig, Ryan Hansen, Snezana Milutinovic, Jason Christiansen, Zachary D. Hornby, Sudhir Chowdhry, Anthony Celeste, Kristen Turner, Deepti Wilkinson
  • Checkpoint kinase 1 (CHK1) inhibitors and uses thereof
    Patent number: 11707462
    Abstract: Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a Chk1 inhibitor disclosed herein.
    Type: Grant
    Filed: August 29, 2022
    Date of Patent: July 25, 2023
    Assignee: BOUNDLESS BIO, INC.
    Inventors: Anthony B. Pinkerton, Stephen Todd Meyer, Jacques Mauger, Yen Pham Hong Truong, Rachelle Janette Elsdon
  • Replication stress pathway agent compositions and methods for treating cancer
    Patent number: 11642345
    Abstract: Provided herein are methods of treating cancer in a subject, wherein the cancer is extrachromosomal DNA-positive (ecDNA-positive) or therapeutically resistant, the method comprising administering to the subject a therapeutically effective amount of a replication stress (RS) pathway agent alone or in combination with a targeted therapeutic.
    Type: Grant
    Filed: October 21, 2022
    Date of Patent: May 9, 2023
    Assignee: BOUNDLESS BIO, INC.
    Inventors: Christian Hassig, Ryan Hansen, Snezana Milutinovic, Jason Christiansen, Zachary Hornby, Sudhir Chowdhry, Anthony Celeste, Kristen Turner, Deepti Wilkinson
  • Replication stress pathway agent compositions and methods for treating cancer
    Patent number: 11547711
    Abstract: Provided herein are methods of treating cancer in a subject, wherein the cancer is extrachromosomal DNA-positive (ecDNA-positive) or therapeutically resistant, the method comprising administering to the subject a therapeutically effective amount of a replication stress (RS) pathway agent alone or in combination with a targeted therapeutic.
    Type: Grant
    Filed: January 4, 2022
    Date of Patent: January 10, 2023
    Assignee: BOUNDLESS BIO, INC.
    Inventors: Christian Hassig, Ryan Hansen, Snezana Milutinovic, Jason Christiansen, Zachary Hornby, Sudhir Chowdhry, Anthony Celeste, Kristen Turner, Deepti Wilkinson